Il Trattamento Del Carcinoma Del Colon-Retto Il Contributo Dell'Oxaliplatino

Bleiberg H. : Role of chemotherapy for advanced colorectal cancer: new opportunities. Semin. Oncol., 23: 42–50, 1996.

Cunningham D. , Findlay M. : The chemotherapy of colon cancer can no longer be ignored. Eur. J. Cancer., 29A: 2077–2079, 1993.

Moertel C.G. : Chemotherapy for colorectal cancer. NEJM, 330: 1136–1142, 1993.

de Gramont A. , Krulik M. , Cady J. , Legadec B. , Maisani J.E. , Loiseau J.P. , Grange J.D. , Gonzalez-Canali G. , Demuynck B. , Lovet C. : High dose folinic acid and 5-FU bolus and continuous infusion in advanced colorectal cancer. Eur. J. Cancer Clin. Oncol., 24: 1499–1503, 1988.

Extra J.M. , Marty M. , Brienza S. , Misset J.L. : Pharmacokinetics and safety profile of oxaliplatin. Semin. Oncol., 25(suppl. 5): 13–22, 1988.

Raymond E. , Chaney S.G. , Taamma A. , Cvitkovic E. : Oxaliplatin: a review of preclinical and clinical studies. Ann. Oncol., 9: 1053–1071, 1998.

Becouarn Y. , Rougier P. : Clinical efficacy of oxaliplatin monochemotherapy: phase II trials in advanced colorectal cancer. Semin. Oncol., 25(suppl. 2): 23–31, 1998.

Bleiberg H. , de Gramont A. : Oxaliplatin plus 5-FU: clinical experience in patients with advanced colorectal cancer. Semin. Oncol., 25(suppl. 5): 32–39, 1998.

Becouarn Y , Ychou M. , Ducreux M. : Oxaliplatin (L-OHP) as first line chemotherapy in metastatic colorectal cancer (MCRC) patients: preliminary activity/toxicity report. Proc. Am. Soc. Clin. Oncol., 16: 229, 1997.

Diaz Rubio E. , Sastre J. , Zaniboni A. , Labianca R. , Cortes-Funes H. , De Braud F. , Boni C. , Benavides M. , Dallavalle G. , Homerin M. : Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: a phase II multicentric study. Ann. Oncol., 9: 105–108, 1998.

Machover D. , Diaz Rubio E. , de Gramont A. , Schilf A. , Gastiaburu J.J. , Brienza S. , Itzhaki M. , Metzger G. , N'Daw D. , Vignoud J. , Abad A. , Francois E. , Gamelin E. , Marty M. , Sastre J. , Seitz J. , Ychou M. : Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann. Oncol., 7: 95–98, 1996.

Lévi F. , Perpoint B. , Garufi C. , Chollet P. , Depres-Brummer P. , Zidani R. , Brienza S. , Itzhaki M. , Iacobelli S. : Oxaliplatin activity against metastatic colorectal cancer. A phase II study of five-day continuous venous infusion at circadian rythm modulated rate. Eur. J. Cancer, 9: 1280–1284, 1993.

Lévi F. , Misset L. , Brienza S. : A chronopharmacologic phase II clinical trial with 5-FU, folinic acid and oxaliplatin using an ambulatory multichannel programmable pump. Cancer, 69: 893–900, 1992.

Lévi F. , Dogliotti L. , Perpoint B. : A multicenter phase II trial of intensified chronotherapy with oxaliplatin (L-OHP), 5-FU and folinic acid in patients with previously untreated metastatic colorectal cancer (MCC). Proc. Am. Soc. Clin. Oncol., 16: 266, 1997.

Lévi F.A. , Zidani R. , Vannetzel J.M. , Perpoint B. , Focan C. , Faggiuolo R. , Chollet P. , Garufi C. , Itzhaki M. , Dogliotti L. : Chronomodulated vs fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, 5-FU and folinic acid in patients with colorectal cancer metastases: a randomized multi-institutional trial. J. Natl. Cancer. Inst., 86: 1608–1617, 1994.

Lévi F. , Zidani R. , Misset J.L. : Randomised multicentre trial of chronotherapy with oxaliplatin, 5-FU and folinic acid in metastatic colorectal cancer. Lancet, 350: 681–686, 1997.

Giacchetti S. , Zidani R. , Perpoint B. , Pinel M.C. , Faggiuolo R. , Focan C. : Phase III trial of 5-FU folinic acid with or without oxaliplatin in previously untreated patients with metastatic colorectal cancer (MCC). Proc. Am. Soc. Clin. Oncol., 16: 229, 1997.

de Gramont A. , Finger A. , Seymour M. , Homerin M. , leBail N. : A randomized trial of leucovorin and 5-FU with or without oxaliplatin in advanced colorectal cancer. Proc. Am. Soc. Clin. Oncol., 17: 257, 1998.

de Gramont A. , Gastiaburu J. , Tournigand C. : Oxaliplatin with high dose folinic acid and 5-FU 48-hour infusion in pretreated metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol., 13: 220, 1994.

de Gramont A. , Vignoud J. , Tournigand C. , Louvet C. , Andre T. , Varette C. , Raymond E. , Moreau S. , leBail N. , Krulik M. : Oxaliplatin with high dose leucovorin and 5-FU 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur. J. Cancer, 33: 214–219, 1997.

Andre T. , Bensmaine M.A. , Louvet C. : Addition of oxaliplatin to the same leucovorin and 5-FU bimonthly regimen after progression in patients with metastatic colorectal cancer (MCRC): preliminary report. Proc. Am. Soc. Clin. Oncol., 16: 270, 1997.

Bertheault-Cvitkovic F. , Jami A. , Itzhaki M. : Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, 5-FU and leucovorin in patients with metastatic colorectal cancer. J. Clin. Oncol., 14: 2950–2958, 1996.

Garufi C. , Brienza S. , Bensmaine M.A. : Addition of oxaliplatin (L-OHP) to chronomodulated 5-FU and folinic acid for reversal of acquired chemoresistance in patients with advanced colorectal cancer. Proc. Am. Soc. Clin. Oncol., 14: 192, 1995.

Louvet C. , Bleiberg H. , Gamelin E. : Oxaliplatin synergistic clinical activity with 5-FU in FU-resistant colorectal cancer patients is independent of FU ± folinic acid schedule. Proc. Am. Soc. Clin. Oncol., 15: 206, 1996.

Van Cutsem E. , Szanto J. , Roth A. , Humblet Y. , Kohne C.H. , Wils J. , Lorenz M. , Borner M. , Schoffski P. , Tabah-Fish I. : Evaluation of the addition of oxaliplatin to the same MAYO or German 5-FU regimen in advanced refractory colorectal cancer. Proc. Am. Soc. Clin. Oncol., 18: 234, 1999.

Bleiberg H. , Brienza S. , Gerard B. , Di Leo A. , Hendlisz A. , VanDaele D. , Cornez N. , Geurs F. , Duriau D. , Bertaux B. : Oxaliplatin combined with a high dose, 24-hour continuous 5-FU infusion and folinic acid based regimen in patients with advanced colorectal cancer. Proc. Am. Soc. Clin. Oncol., 18: 241, 1999.

Zori-Comba A. , Blajman C. , Richardet E. , Vilanova M. , Coppola F. , VanKooten M. , Rodger J. , Giglio R. , Balbiani L. , Perazzo F. , Montiel M. , Chacon M. , Pujol E. , Mickiewicz E. , Cazap E. , Recondo G. , Kotliar M. , Nesis P. , Reale M. , Lastiri F. : Bimonthly oxaliplatin (L-OHP) with or withouth 5-FU and leucovorin: proven evidence of synergism in a phase II randomised trial. Proc. Am. Soc. Clin. Oncol., 18: 248, 1999.

Bensmaine M.A. , Mary M. , de Gramont A. , Misset J.L. , Cuvier C. , Chollet P. , Conroy T. , Chauvenet L. , Ducreux M. , Maplaige P. , Untereiner M. , Jacob J.H. , Gamelin E. , Sutherland W. , Cvitkovic E. : Extended access French program (EAFP) of oxaliplatin ± 5-FU in 5-FU refractory advanced colorectal cancer patients. Proc. Am. Soc. Clin. Oncol., 18: 253, 1999.

Maindrault-Goebel F. , de Gramont A. , Louvet C. , Andre T. , Carola E. , Gilles-Amar V. , Lotz J.P. , Izrael V. , Krulik M. : High dose oxaliplatin with the simplified 48h bimonthly leucovorin and 5-FU regimen in pretreated metastatic colorectal cancer (FOLFOX). Proc. Am. Soc. Clin. Oncol., 18: 265, 1999.

Abad A. , Navarro M. , Sastre J. , Cervantes A. , Anton A. , Marcuello E. , Carrato A. , Aranda E. , Massuti B. , Guillot M. , Garcia M. , Diaz Rubío E. , Mounedji-Boudiaf L. , Llados F. : Biweekly oxaliplatin plus weekly 48 h continuous infusion 5-FU in first line treatment of advanced colorectal cancer (preliminary results). Proc. Am. Soc. Clin. Oncol., 18: 275, 1999.

Kouroussis C. , Mavroudis D. , Giannakakis T. , Ziras N. , Athanasiadis A. , Kakolyris S. , Androulakis N. , Kalbakis K. , Agelaki S. , Souglakos J. , Sarra E. , Vardakis N. , Georgoulias V. : Biweekly oxaliplatin (L-OHP) with high dose leucovorin and 5-FU 48-hour continuous infusion in pretreated patients with advanced colorectal cancer. Proc. Am. Soc. Clin. Oncol., 18: 290, 1999.

Roca E. , Montiel M. , Barugel M. , Rodriguez M.C. , Ballarino G. , Kotliar M. , Carraro S. : 5-FU and leucovorin (MAYO regimen) plus bimonthly oxaliplatin in patients with advanced colorectal cancer. Proc. Am. Soc. Clin. Oncol., 18: 298, 1999.

Vassilaki M. , Tsiapara S. , Desses N. , Pavlidis T. , Parassiris V. , Linos D. : First line chemotherapy with oxaliplatin (L-OHP) + 5-FU + leucovorin in patients with metastatic colorectal cancer. Preliminary results of a phase II study. Proc. Am. Soc. Clin. Oncol., 18: 303, 1999.

Janinis J. , Fountzilas G. , Skarlos D.V. , Efstathiou E. , Aravantinos G. , Papakostas P. : Second line combination chemotherapy with weekly oxaliplatin and high dose 5-FU with leucovorin in metastatic colorectal carcinoma. A Hellenic Cooperative Oncology Group Study. Proc. Am. Soc. Clin. Oncol., 18: 255, 1999.

Sun Y , Guan Z.Z. , Jin M.L. , Shi T.Z. , Li W.L. , Zhou L.Z. , Sui G.J. , Li L.Q. , Xu L.G. , Zhang J.Q. , Song S.P. , Li R. , Xu D.F. , Li Y. , Huang F.L. , Brienza S. , Ju L.Y. : A multicenter randomised phase II trial of oxaliplatin alone and in combination in patients with advanced colorectal cancer in China. Proc. Am. Soc. Clin. Oncol., 18: 255, 1999.